Abstract:Tetraploid (4N) cells are considered important in cancer because they can display increased tumorigenicity, resistance to conventional therapies, and are believed to be precursors to whole chromosome aneuploidy. It is therefore important to determine how tetraploid cancer cells arise, and how to target them. P53 is a tumor suppressor protein and key regulator of tetraploidy. As part of the "tetraploidy checkpoint", p53 inhibits tetraploid cell proliferation by promoting a G1-arrest in incipient tetraploid cells (referred to as a tetraploid G1 arrest). Nutlin-3a is a preclinical drug that stabilizes p53 by blocking the interaction between p53 and MDM2. In the current study, Nutlin-3a promoted a p53-dependent tetraploid G1 arrest in two diploid clones of the HCT116 colon cancer cell line. Both clones underwent endoreduplication after Nutlin removal, giving rise to stable tetraploid clones that showed increased resistance to ionizing radiation (IR) and cisplatin (CP)-induced apoptosis compared to their diploid precursors. These findings demonstrate that transient p53 activation by Nutlin can promote tetraploid cell formation from diploid precursors, and the resulting tetraploid cells are therapy (IR/CP) resistant. Importantly, the tetraploid clones selected after Nutlin treatment expressed approximately twice as much P53 and MDM2 mRNA as diploid precursors, expressed approximately twice as many p53-MDM2 protein complexes (by co-immunoprecipitation), and were more susceptible to p53-dependent apoptosis and growth arrest induced by Nutlin. Based on these findings, we propose that p53 plays novel roles in both the formation and targeting of tetraploid cells. Specifically, we propose that 1) transient p53 activation can promote a tetraploid-G1 arrest and, as a result, may inadvertently promote formation of therapy-resistant tetraploid cells, and 2) therapy-resistant tetraploid cells, by virtue of having higher P53 gene copy number and expressing twice as many p53-MDM2 complexes, are more sensitive to apoptosis and/or growth arrest by anti-cancer MDM2 antagonists (e.g. Nutlin).

Nuclear stabilization of p53 requires a functional nucleolar surveillance pathway

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Inhibition of Nonsense-Mediated Decay Rescues Functional P53β/γ Isoforms in MDM2-amplified Cancers

P53 and P21(waf1) Are Recruited to Distinct PML-Containing Nuclear Foci in Irradiated and Nutlin-3a-Treated U2OS Cells

SIRT7-dependent deacetylation of NPM promotes p53 stabilization following UV-induced genotoxic stress.

A redox mechanism underlying nucleolar stress sensing by nucleophosmin

Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability

Modeling the Etiology of p53-mutated Cancer Cells

Novel Roles For P53 In The Genesis And Targeting Of Tetraploid Cancer Cells

PIM1 destabilization activates a p53-dependent response to ribosomal stress in cancer cells

Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress

Homeostatic Regulation of Base Excision Repair by A P53-Induced Phosphatase - Linking Stress Response Pathways with Dna Repair Proteins

Nucleo-cytoplasmic environment modulates spatiotemporal p53 phase separation

Nucleolar Stress: Hallmarks, Sensing Mechanism and Diseases

p53 dynamics vary between tissues and are linked with radiation sensitivity

Scission of the P53-Mdm2 Loop by Ribosomal Proteins.

Nucleolar protein NOC4L inhibits tumorigenesis and progression by attenuating SIRT1-mediated p53 deacetylation

Metabolic regulation by p53 prevents R-loop-associated genomic instability

p53 engagement is a hallmark of an unfolded protein response in the nucleus of mammalian cells

Nucleolar Stress Response via Ribosomal Protein L11 Regulates Topoisomerase Inhibitor Sensitivity of P53-Intact Cancers